Elan in €45m deal with British biotech firm
Pharmaceutical giant Elan is to receive $55m (€45.07m) from British biotech firm Vernalis for the North American commericialisation rights to migraine treatment Frova.
Vernalis, formed from a merger of RiboTargets and Vernalis Group, changed its name to Vernalis in 2003.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





